IP Library Granted Patent US 10,465,196
Granted Patent B2
US 10,465,196 · App. 15/969,374 · Granted Nov 5, 2019

Treatment of C9FTD/ALS by targeting RNA expanded repeat sequences

Inventor: Matthew D. Disney (Jupiter, FL)
Assignee: The Scripps Research Institute
C12N15/63A61K31/404A61K31/7105C07D209/14C07D209/42C07D471/04C07H21/02C12N15/113A61K38/00A61K48/00C12N2310/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,465,196
App. No.
15/969,374
Granted
Nov 5, 2019
Kind
B2
Abstract

A repeat expansion in C9ORF72 causes frontotemporal dementia and amyotrophic lateral sclerosis (c9FTD/ALS). RNA of the expanded repeat (r(GGGGCC) exp ) forms nuclear foci or undergoes repeat-associated non-ATG (RAN) translation producing “c9RAN proteins”. Since neutralizing r(GGGGCC) exp could inhibit these potentially toxic events, we sought to identify small molecule binders of r(GGGGCC) exp . Chemical and enzymatic probing of r(GGGGCC) 8 indicate it adopts a hairpin structure in equilibrium with a quadruplex structure. Using this model, bioactive small molecules targeting r(GGGGCC) exp were designed and found to significantly inhibit RAN translation and foci formation in cultured cells expressing r(GGGGCC) 66 and neurons trans-differentiated from fibroblasts of repeat expansion carriers. Finally, we show that poly(GP) c9RAN proteins are specifically detected in c9ALS patient cerebrospinal fluid. Our findings highlight r(GGGGCC) exp -binding small molecules as a possible c9FTD/ALS therapeutic, and suggest c9RAN proteins could potentially serve as a pharmacodynamic biomarker to assess efficacy of therapies that target r(GGGGCC) exp .

Claims (4)

1. A method of inhibiting repeat-associated non-ATG (RAN) translation and foci formation in cultured cells expressing r(GGGGCC) 66 and neurons trans-differentiated from fibroblasts of repeat expansion carriers, comprising contacting the cells with an effective amount of a compound of formula 3

or a pharmaceutically acceptable salt thereof.

2. A method of treating a patient afflicted with ALS or FTD, comprising administering to the patient an effective dose of a compound of formula 3

or a pharmaceutically acceptable salt thereof.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2022
From: DISNEY, MATTHEW D.
To: THE SCRIPPS RESEARCH INSTITUTE
Reel/Frame 061183/0099 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2022
From: THE SCRIPPS RESEARCH INSTITUTE
To: UNIVERSITY OF FLORIDA BOARD OF TRUSTEES
Reel/Frame 061177/0338 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2022
From: UNIVERSITY OF FLORIDA BOARD OF TRUSTEES
To: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
Reel/Frame 061177/0491 →
Continuity (3)
Continuation 15503524
Provisional Application 62036721 · Aug 13, 2014
Related Publication 20180334678A1 · Nov 22, 2018